While the evolution of targeted therapies has significantly improved outcomes and quality of life in patients with advanced non-small cell lung cancer (NSCLC), it can be difficult to keep up with recent advances in this field. The Association of Community Cancer Centers (ACCC)—in partnership with the American Society for Clinical Pathology (ASCP)—is committed to ensuring you have the resources, tools, and education you need to optimize the diagnosis, testing, and management of patients with advanced NSCLC, particularly those with ALK mutations.
This enduring material was recorded from a half-day, interactive, CME/CMLE-accredited virtual (live) summit to help members of the cancer care team enhance their coordination of patient care and gain deeper scientific knowledge, skills, and competence in biomarker testing practices, treatment selection, and management of adverse events in patients with advanced NSCLC.
Each highly interactive session is presented by an interprofessional faculty team, features rich scenarios and patient cases involving advanced NSCLC, and introduces the patient perspective to address the following topics:
Educational activities funded by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer, Inc.
While ADCs have emerged as a promising development for patients with NSCLC, they present unique challenges in clinical practice, such as optimal patient selection, treatment sequencing, and toxicity management. ADCs can also elicit significant adverse events, particularly when combined with immunotherapy, raising concerns about overlapping toxicities and the need for close monitoring for treatment-related complications.